Aussie Try To Lower Drug Costs Ends Up Raising Most, Report Says
This article was originally published in PharmAsia News
Australia's attempt to lower the cost and obtain a better drug value under its health-insurance plan appears to have backfired, according to a report
You may also be interested in...
Becton Dickinson will spend $1.2bn over the next four years to improve its drug-delivery device manufacturing capabilities. See what Eric Borin, president of BD, said about it here.
Pfizer is producing vaccine doses at scale now that it has buttoned down the manufacturing process.
In second letter this year targeting email communications, OPDP says that putting the methotrexate oral solution’s risk information below the signature block does not offer ‘prominence and readability’ comparable to the information on the drug’s effectiveness for the treatment of acute lymphoblastic leukemia that was in the body of the email.